SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated July 16, 2003
(Commission File No. 1-15024)
---------------
Novartis AG
(Name of Registrant)
----------
Lichtstrasse 35
4056 Basel
Switzerland
----------
(Address of Principal Executive Offices)
----------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F: |X| Form 40-F: |_|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes: |_| No: |X|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes: |_| No: |X|
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: |_| No: |X|
Enclosures: Novartis IR invtitation to the Novartis Half Year Sales &
Results 2003 Conference Call
Page 1 of 4 Total Pages
Investor Relations Novartis International AG
CH-4002 Basel
Switzerland
[LOGO] NOVARTIS
Novartis Corporation
608 Fifth Avenue
New York, NY 10020
USA
- Investor Relations Invitation -
Half Year Sales & Results 2003 Conference Call
Dear Investor,
We are pleased to invite you to our Half Year Sales & Results 2003 Conference
Call. Please find below the dial-in details:
Date: Monday, July 21st, 2003
Time: 06.00 p.m. Switzerland
05.00 p.m. UK
12.00 p.m. New York
Advisable: dial-in 10 minutes before
Phone numbers: +41 91 610 56 00 Europe and ROW
+800 2467 8700 Toll free Europe and ROW
+44 207 866 4111 UK
+1800 860 2442 Toll free USA and Japan
+1 866 519 5086 Toll free Canada
+1 866 519 5087 Toll free Mexico
You may access the conference call as a live audio webcast on the Internet on
July 21st: http://www.novartis.com/investors.
Additional financial information will be available on Monday, July 21st, on the
Internet http://www.novartis.com/investors
Page 2 of 4 Total Pages
Playback for 48 hours, starting
Date: Monday, July 21st, 2003
Time: 09.00 p.m. Switzerland
08.00 p.m. UK
03.00 p.m. New York
Phone numbers: +41 91 612 4330 Europe and ROW
+44 207 866 4300 UK
+1 877 344 7529 US
Dial-in code: 431 (followed by the # sign)
###
Novartis Global Investor Relations Novartis North America Investor Relations
---------------------------------- -----------------------------------------
Karen J. Huebscher, Ph.D. +41 61 324 84 33
karen.huebscher@group.novartis.com
Nafida Bendali +41 61 324 35 14 Kamran Tavangar, Ph.D. +1 212 830 24 33
nafida.bendali@group.novartis.com kamran.tavangar@group.novartis.com
Katharina Furrer +41 61 324 53 16 John Menditto +1 212 830 24 44
katharina.furrer@group.novartis.com john.menditto@group.novartis.com
Alex Kelly +41 61 324 62 89 Sabine Moravi +1 212 830 24 56
alex.kelly@group.novartis.com sabine.moravi@group.novartis.com
Sean Wells +41 324 33 34 Jill Pozarek +1 212 830 24 45
sean.wells@group.novartis.com jill.pozarek@group.novartis.com
Silke Zentner +41 61 324 86 12 Fax: +1 212 830 24 05
silke.zentner@group.novartis.com www.novartis.com
Fax: +41 61 324 84 44
www.novartis.com
Page 3 of 4 Total Pages
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
Novartis AG has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NOVARTIS AG
Date: July 17, 2003 By: /s/ MALCOLM CHEETHAM
--------------------
Name: Malcolm Cheetham
Title: Head Group Financial Reporting
and Accounting
Page 4 of 4 Total Pages